Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06336304 · ClinicalTrials.gov registry record
NXT Post-Market Clinical Follow-up
A clinical trial of Urinary Incontinence and Urinary Incontinence, Urge, sponsored by Laborie Medical Technologies.
- Recruiting
- Registry status
- 180
- Enrollment target
- 4
- Study locations
NCT06336304: Recruiting study of Urinary Incontinence and Urinary Incontinence, Urge, sponsored by Laborie Medical Technologies.
NCT06336304 is a study of Urinary Incontinence and Urinary Incontinence, Urge that is actively recruiting participants, run by Laborie Medical Technologies. The registered enrollment target is 180 participants, below the 258-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (30% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06336304, a study of Urinary Incontinence and Urinary Incontinence, Urge, is actively recruiting participants, sponsored by Laborie Medical Technologies.
- RECRUITING
- Registry status
- 180 participants
- Enrollment target
- 4
- Study locations
Study Summary
NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation to Confirm Ongoing Safety and Performance in Urodynamic Patient Sub-Populations
Primary Outcome
Assess the proportion of affirmative responses to the question: did the NXT system successfully measure all necessary urodynamic parameters you required for this patient?
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Urodynamic procedure
Study Locations (4)
Maryland
- Chesapeake Urology Hanover - Hanover
- Chesapeake Urology Owing Mills - Owing Mills
Ohio
- Ohio State University - Columbus
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2024-06-18 |
| Est. Completion | 2025-12 |
What NCT06336304 shows while recruiting
NCT06336304 is an observational study that tracks outcomes without assigning an intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 258-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (30% lower).
The record links to 5 conditions, with Urinary Incontinence appearing as the primary indexed condition, and to 1 intervention - of which Urodynamic procedure is the first listed.
NCT06336304 reports a single indexed study location in Maryland, Ohio, Virginia.
Frequently Asked Questions
What is clinical trial NCT06336304 about?
NCT06336304 is a clinical study titled "NXT Post-Market Clinical Follow-up". NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation to Confirm Ongoing Safety and Performance in Urodynamic Patient Sub-Populations
What is the current status of trial NCT06336304?
This trial is currently recruiting. The enrollment target is 180 participants. The study started on 2024-06-18. Estimated completion is 2025-12.
What conditions does trial NCT06336304 study?
This clinical trial studies the following conditions: Urinary Incontinence, Urinary Incontinence, Urge, Urinary Bladder, Overactive, Urinary Bladder, Neurogenic, Urinary Obstruction.
What interventions are being tested in trial NCT06336304?
The interventions under investigation include: Urodynamic procedure (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06336304?
This trial is sponsored by Laborie Medical Technologies, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06336304 being conducted?
This trial has 4 study locations across Maryland, Ohio, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Incontinence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06336304's enrollment target sits among peer trials
180 16th of 48 higher than 33 of 48 other Urinary Incontinence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urinary Incontinence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
RECRUITING · NA
-
TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.
RECRUITING · NA
-
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
RECRUITING · NA
-
Improving Overactive Bladder Treatment Access and Adherence
RECRUITING · NA
-
Training for Urinary Leakage Improvement After Pregnancy
RECRUITING · NA
-
Muscle Fiber Fragment Treatment for Urinary Incontinence
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI